{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:50Z","timestamp":1740107450494,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY850"],"award-info":[{"award-number":["2024KY850"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274020"],"award-info":[{"award-number":["82274020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04702-3","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:01:32Z","timestamp":1722391292000},"page":"523-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"94","author":[{"given":"Dihong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Like","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"4","key":"4702_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.Ccr-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317\u20131324. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1634","journal-title":"Clin Cancer Res"},{"issue":"25","key":"4702_CR2","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1200\/jco.18.01842","volume":"37","author":"M Untch","year":"2019","unstructured":"Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, K\u00fcmmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S (2019) NAB-Paclitaxel improves Disease-Free Survival in early breast Cancer: GBG 69-GeparSepto. J Clin Oncol 37(25):2226\u20132234. https:\/\/doi.org\/10.1200\/jco.18.01842","journal-title":"J Clin Oncol"},{"issue":"22","key":"4702_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"issue":"3","key":"4702_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, K\u00fcmmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345\u2013356. https:\/\/doi.org\/10.1016\/s1470-2045(15)00542-2","journal-title":"Lancet Oncol"},{"issue":"11","key":"4702_CR5","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.Ccr-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11(11):4136\u20134143. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2291","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4702_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1041\u20131053. https:\/\/doi.org\/10.1517\/14656566.7.8.1041","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"4702_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA (2013) Nab-Paclitaxel mechanisms of action and delivery. J Control Release 170(3):365\u2013372. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.041","journal-title":"J Control Release"},{"issue":"6","key":"4702_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00280-008-0828-1","volume":"63","author":"JB Bulitta","year":"2009","unstructured":"Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035\u20131048. https:\/\/doi.org\/10.1007\/s00280-008-0828-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4702_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1200\/jco.2002.20.2.574","volume":"20","author":"H Gelderblom","year":"2002","unstructured":"Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20(2):574\u2013581. https:\/\/doi.org\/10.1200\/jco.2002.20.2.574","journal-title":"J Clin Oncol"},{"issue":"31","key":"4702_CR10","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/jco.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794\u20137803. https:\/\/doi.org\/10.1200\/jco.2005.04.937","journal-title":"J Clin Oncol"},{"issue":"1","key":"4702_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2014-0202","volume":"20","author":"A Hurria","year":"2015","unstructured":"Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, Katheria V, Rotter AJ, Wong C, Choi A, Feng T, Ramani R, Doan CM, Brown J, Somlo G (2015) Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist 20(1):37\u201344. https:\/\/doi.org\/10.1634\/theoncologist.2014-0202","journal-title":"Oncologist"},{"issue":"25","key":"4702_CR12","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/jco.2005.11.013","volume":"23","author":"NK Ibrahim","year":"2005","unstructured":"Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019\u20136026. https:\/\/doi.org\/10.1200\/jco.2005.11.013","journal-title":"J Clin Oncol"},{"issue":"1","key":"4702_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1186\/s12885-021-08441-z","volume":"21","author":"H Lu","year":"2021","unstructured":"Lu H, Zha S, Zhang W, Wang Q, Jiang D, Xu X, Zheng X, Qiu M, Shan C (2021) A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. BMC Cancer 21(1):830. https:\/\/doi.org\/10.1186\/s12885-021-08441-z","journal-title":"BMC Cancer"},{"issue":"15","key":"4702_CR14","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.Ccr-21-4363","volume":"28","author":"PN Munster","year":"2022","unstructured":"Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC (2022) Overcoming Taxane Resistance: preclinical and phase 1 studies of Relacorilant, a selective glucocorticoid receptor modulator, with Nab-Paclitaxel in solid tumors. Clin Cancer Res 28(15):3214\u20133224. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4363","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4702_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcph.304","volume":"54","author":"N Chen","year":"2014","unstructured":"Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54(10):1097\u20131107. https:\/\/doi.org\/10.1002\/jcph.304","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4702_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-020-04140-x","volume":"86","author":"T Tsushima","year":"2020","unstructured":"Tsushima T, Kasai H, Tanigawara Y (2020) Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer. Cancer Chemother Pharmacol 86(4):487\u2013495. https:\/\/doi.org\/10.1007\/s00280-020-04140-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"4702_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","volume":"15","author":"K Campbell","year":"2022","unstructured":"Campbell K, Chadha N, Dimri S, Wang W, Li E (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Rev Hematol 15(7):619\u2013633. https:\/\/doi.org\/10.1080\/17474086.2022.2093712","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"4702_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295\u2013306. https:\/\/doi.org\/10.2165\/11586040-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4702_CR19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1124\/dmd.116.073148","volume":"44","author":"ST Stern","year":"2016","unstructured":"Stern ST, Martinez MN, Stevens DM (2016) When is it important to measure unbound drug in evaluating Nanomedicine Pharmacokinetics? Drug Metab Dispos 44(12):1934\u20131939. https:\/\/doi.org\/10.1124\/dmd.116.073148","journal-title":"Drug Metab Dispos"},{"key":"4702_CR20","doi-asserted-by":"publisher","first-page":"123437","DOI":"10.1016\/j.ijpharm.2023.123437","volume":"646","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Xie L, Tang L, Xiao D, Shi W, Wang Y, Li Y, Han X, Ying X, Zheng Y (2023) A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia. Int J Pharm 646:123437. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123437","journal-title":"Int J Pharm"},{"issue":"20","key":"4702_CR21","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/jco.2001.19.20.4065","volume":"19","author":"A Henningsson","year":"2001","unstructured":"Henningsson A, Karlsson MO, Vigan\u00f2 L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19(20):4065\u20134073. https:\/\/doi.org\/10.1200\/jco.2001.19.20.4065","journal-title":"J Clin Oncol"},{"issue":"8","key":"4702_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/s0959-8049(03)00126-6","volume":"39","author":"A Henningsson","year":"2003","unstructured":"Henningsson A, Sparreboom A, Sandstr\u00f6m M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39(8):1105\u20131114. https:\/\/doi.org\/10.1016\/s0959-8049(03)00126-6","journal-title":"Eur J Cancer"},{"issue":"6","key":"4702_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00280-008-0827-2","volume":"63","author":"JB Bulitta","year":"2009","unstructured":"Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus taxol in cancer patients. Cancer Chemother Pharmacol 63(6):1049\u20131063. https:\/\/doi.org\/10.1007\/s00280-008-0827-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"4702_CR24","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.Ccr-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14(13):4200\u20134205. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4592","journal-title":"Clin Cancer Res"},{"key":"4702_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jchromb.2016.12.015","volume":"1046","author":"S Malhi","year":"2017","unstructured":"Malhi S, Stesco N, Alrushaid S, Lakowski TM, Davies NM, Gu X (2017) Simultaneous quantification of reparixin and paclitaxel in plasma and urine using ultra performance liquid chromatography-tandem mass spectroscopy (UHPLC-MS\/MS): application to a preclinical pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci 1046:165\u2013171. https:\/\/doi.org\/10.1016\/j.jchromb.2016.12.015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"4702_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cpdd.803","volume":"10","author":"Y Li","year":"2021","unstructured":"Li Y, Kassir N, Chen N, Wang X, Palmisano M, Zhou S (2021) Population Pharmacokinetics and exposure-response analysis of nab-Paclitaxel in Pediatric patients with recurrent or refractory solid tumors. Clin Pharmacol Drug Dev 10(2):115\u2013130. https:\/\/doi.org\/10.1002\/cpdd.803","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"4702_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10637-011-9674-9","volume":"30","author":"I Okamoto","year":"2012","unstructured":"Okamoto I, Yamamoto N, Kubota K, Ohe Y, Nogami N, Murakami H, Yamaya H, Ono K, Nakagawa K (2012) Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer. Invest New Drugs 30(3):1132\u20131137. https:\/\/doi.org\/10.1007\/s10637-011-9674-9","journal-title":"Invest New Drugs"},{"issue":"1","key":"4702_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","volume":"57","author":"TB Stage","year":"2018","unstructured":"Stage TB, Bergmann TK, Kroetz DL (2018) Clinical pharmacokinetics of Paclitaxel Monotherapy: an updated literature review. Clin Pharmacokinet 57(1):7\u201319. https:\/\/doi.org\/10.1007\/s40262-017-0563-z","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4702_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/jco.1995.13.1.180","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Kearns CM, Giani A, Capri G, Vigan\u00f3 L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180\u2013190. https:\/\/doi.org\/10.1200\/jco.1995.13.1.180","journal-title":"J Clin Oncol"},{"issue":"7","key":"4702_CR30","first-page":"1454","volume":"59","author":"A Sparreboom","year":"1999","unstructured":"Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59(7):1454\u20131457","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04702-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:24Z","timestamp":1727535744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04702-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4702"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04702-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Fourth Hospital of Hebei Medical University, Guizhou Cancer Hospital, and Affiliated Hospital of Hebei University. The bioequivalence study permit numbers are as follows: China National Medical Products Administration (NMPA) registration No. CYHB1900621.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}